Metabolic
Tirzepatide
GIP/GLP-1 dual agonist · LY3298176
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.
5 mg10 mg15 mg20 mg30 mg +5
Semaglutide
Also known as: GLP-1 receptor agonist · NN9535
Metabolic & GLP-1 In stock Box of 10 vials 1 reference
Long-acting GLP-1 receptor agonist — the reference compound for incretin-based metabolic research.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| SM5 | 5 mg | 10 vials / box | |
| SM10 | 10 mg | 10 vials / box | |
| SM15 | 15 mg | 10 vials / box | |
| SM20 | 20 mg | 10 vials / box | |
| SM30 | 30 mg | 10 vials / box |
Order Semaglutide
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
Semaglutide is a 31-amino-acid glucagon-like peptide-1 (GLP-1) analogue engineered with a C18 fatty-diacid side chain that binds albumin, extending its half-life to roughly one week. It activates the GLP-1 receptor, which is expressed in pancreatic islets, the gastrointestinal tract and hypothalamic appetite circuits.
In the 68-week STEP 1 trial (n = 1,961), once-weekly semaglutide 2.4 mg produced a mean body-weight change of −14.9% versus −2.4% with placebo in adults with overweight or obesity 1. It is among the most extensively characterised peptides in the metabolic literature and serves as the benchmark against which newer incretin compounds are compared.
At a glance
- GLP-1 receptor agonist with ~1-week half-life (albumin-binding fatty-diacid side chain)
- Phase 3 evidence base: STEP programme, SUSTAIN programme
- Lyophilized; supplied in 5, 10, 15, 20 and 30 mg vials
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
- Sequence
- H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-C18-diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
- Formula
- C187H291N45O59
- Mol. weight
- 4113.6 g/mol
- CAS No.
- 910463-68-2
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.
Related
Often ordered together
Metabolic
Retatrutide
GGG triple agonist · LY3437943
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
5 mg10 mg15 mg20 mg30 mg +4
Metabolic Blend
Cagrilintide + Semaglutide
CagriSema blend · Amylin + GLP-1 combination
Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.
5 mg (2.5 + 2.5)10 mg (5 + 5)